MECOM and acute myeloid leukemia: The inversion or translocation of chromosome 3 drives inv(3)/t(3;3) AML via structural rearrangement of an enhancer that upregulates transcription of EVI1. It is associated with poor overall survival in AML patients and HSCT is usually mandated whenever possible (43).